The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type
Open accessAbstract
The clinical activity of rituximab has been evaluated in a phase 2 study in both untreated and relapsed mucosa-associated lymphoid tissue (MALT) lymphomas. Treatment consisted of 4 standard (375 mg/m2) weekly doses. Thirty-five patients were enrolled, and 34 completed the treatment program. The primary lymphoma location was stomach in 15 patients, and extragastric in 20. Eleven patients had previously been treated with chemotherapy. At study entry 12 patients had Ann Arbor stage IE, 3 had stage IIE, and 20 had stage IV disease. The overall response rate was 73% (95% confidence interval, 56%-87%), with 15 complete responses and 10 partial responses, and the response rate was significantly higher in the chemotherapy-naive patients, who had an 87% response rate compared with 45% of the previously treated patients (P =.03). The median response duration was 10.5 months. At a median follow-up of 15 months, 9 patients (26%) relapsed. The median time to treatment failure was 14.2 months in the whole series, but it was significantly longer (22 versus 12 months) in the chemotherapy-naive patients compared with those who had prior chemotherapy (P =.001). Most adverse events were of mild to moderate severity with no grade 4 toxicity. This study indicates that rituximab is safe with significant activity in MALT lymphomas.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
World Health Organization Classification of Tumours
Fletcher, C., van den Berg, A., & Molenaar, I. (2002) · Cited by 7,079
Coiffier, B., Lepage, E., Brière, J., Herbrecht, R., Tilly, H., Bouabdallah, R., Morel, P., Van Den Neste, E., Salles, G., Gaulard, P., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011795 · Cited by 5,574
Applied Nonparametric Statistics
Wozniak, P. J., & Daniel, W. W. (1991) · Technometrics · doi:10.2307/1268795 · Cited by 4,987
Optimal two-stage designs for phase II clinical trials.
Simon, R. (1989) · Controlled Clinical Trials · doi:10.1016/0197-2456(89)90015-9 · Cited by 3,636
Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas
Cheson, B. D., Horning, S. J., Coiffier, B., Shipp, M. A., Fisher, R. I., Connors, J. M., Lister, T. A., Vose, J., Grillo-López, A., Hagenbeek, A., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.4.1244 · Cited by 3,486
McLaughlin, P., Grillo-López, A. J., Link, B. K., Levy, R., Czuczman, M. S., Williams, M. E., Heyman, M. R., Bence-Bruckler, I., White, C. A., Cabanillas, F., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.8.2825 · Cited by 2,755
Coiffier, B., Haïoun, C., Ketterer, N., Engert, A., Tilly, H., Ma, D. D. F., Johnson, P., Lister, A., Feuring‐Buske, M., Radford, J. A., et al. (1998) · PubMed · doi:10.1182/blood.v92.6.1927 · Cited by 893
Czuczman, M. S., Grillo-López, A. J., White, C. A., Saleh, M., Gordon, L., LoBuglio, A. F., Jonas, C., Klippenstein, D., Dallaire, B., & Varns, C. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.1.268 · Cited by 856
Thieblemont, C., Berger, F., Dumontet, C., Moullet, I., Bouafia, F., Felman, P., Salles, G., & Coiffier, B. (2000) · Blood · doi:10.1182/blood.v95.3.802.003k19_802_806 · Cited by 518
Cited by
Rituximab treatment in patients with primary Sjögren's syndrome: An open‐label phase II study
Pijpe, J., van Imhoff, G. W., Spijkervet, F. K. L., Roodenburg, J. L. N., Wolbink, G. J., Mansour, K., Vissink, A., Kallenberg, C. G. M., & Bootsma, H. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21260 · Cited by 500
Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
Zucca, E., Conconi, A., Pedrinis, E., Cortelazzo, S., Motta, T., Gospodarowicz, M. K., Patterson, B. J., Ferreri, A. J. M., Ponzoni, M., Devizzi, L., et al. (2003) · Blood · doi:10.1182/blood-2002-04-1279 · Cited by 487
Self-citationNon-Hodgkin Lymphoma: Diagnosis and Treatment
Ansell, S. M., & Armitage, J. (2005) · Mayo Clinic Proceedings · doi:10.4065/80.8.1087 · Cited by 356
Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Zucca, E., Arcaini, L., Buske, C., Johnson, P. W., Ponzoni, M., Raderer, M., Ricardi, U., Salar, A., Stamatopoulos, K., Thieblemont, C., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2019.10.010 · Cited by 350
Metadata
- Authors
- Conconi, A.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2003-10-15
- Volume
- 102
- Issue
- 8
- Pages
- 2741-2745
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2148613364
- Cited by
- 402
- References
- 27
- FWCI
- 16.83
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. https://app.cochat.ai/papers/10.1182/blood-2002-11-3496
- The paper
- Conconi, A. (2003). Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. Blood. https://doi.org/10.1182/blood-2002-11-3496
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.